Literature DB >> 22660552

Targeting signaling pathways in glomerular diseases.

Carole Henique1, Pierre-Louis Tharaux.   

Abstract

PURPOSE OF REVIEW: Podocytes are highly specialized epithelial cells that line the urinary surface of the glomerular capillary tuft. Dysfunction or death of podocytes impacts glomerular permeability and filtration. Here, we discuss the recent findings about the role of specific cell signaling pathways in glomerular diseases with an emphasis on the molecules in the podocyte that represent candidate therapeutic targets. RECENT
FINDINGS: A number of local endogenous factors that retard the progression of diabetic nephropathy have recently been identified and include angiopoietin-1 (Angpt1), Smad7 and nuclear factor (erythroid-derived 2)-like 2 (Nrf2). Calcium-dependent regulation of podocyte actin dynamics involving transient receptor potential canonical (TRPC) channels and the Rho and Rac small GTPases has been shown to play important functions in glomerular health and disease. A central role for mammalian target of rapamycin (mTOR) activation in the development of diabetic nephropathy and regulation of autophagic flux in podocytes during aging has been demonstrated. Discovery of a circulating factor (suPAR) that can modulate outside-in beta3 integrin signaling in recurrent focal segmental glomerulosclerosis provides exciting therapeutic possibilities. Another secreted factor, the hyposialylated form of angiopoietin-like-protein 4 (ANGPTL4) was found to favor albuminuria in rats and in minimal change disease. Therapeutic sialylation of ANGPTL4 could limit albuminuria. Finally, neutralization of de novo paracrine activation of glomerular epithelial cells by heparin-binding epidermal growth factor (EGF)-like growth factor or EGF receptor antagonists could limit crescent formation and renal failure in immune-mediated vasculitis.
SUMMARY: Here, we review the recent developments in our understanding of signaling pathways required for podocyte function in health and disease. Manipulation of these pathways provides an attractive therapeutic option for glomerular diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22660552     DOI: 10.1097/MNH.0b013e328354a598

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  5 in total

1.  Kindlin-2 Association with Rho GDP-Dissociation Inhibitor α Suppresses Rac1 Activation and Podocyte Injury.

Authors:  Ying Sun; Chen Guo; Ping Ma; Yumei Lai; Fan Yang; Jun Cai; Zhehao Cheng; Kuo Zhang; Zhongzhen Liu; Yeteng Tian; Yue Sheng; Ruijun Tian; Yi Deng; Guozhi Xiao; Chuanyue Wu
Journal:  J Am Soc Nephrol       Date:  2017-08-03       Impact factor: 10.121

Review 2.  Glycemic memories and the epigenetic component of diabetic nephropathy.

Authors:  Samuel T Keating; Assam El-Osta
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

Review 3.  Novel drugs and intervention strategies for the treatment of chronic kidney disease.

Authors:  Hiddo Jan Lambers Heerspink; Dick de Zeeuw
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

4.  What is new in the management of rapidly progressive glomerulonephritis?

Authors:  George H B Greenhall; Alan D Salama
Journal:  Clin Kidney J       Date:  2015-02-19

5.  Dmp1 Promoter-Driven Diphtheria Toxin Receptor Transgene Expression Directs Unforeseen Effects in Multiple Tissues.

Authors:  Ahmed Al-Jazzar; Behzad Javaheri; Matt Prideaux; Alan Boyde; Cheryl L Scudamore; Chahrazad Cherifi; Eric Hay; Mark Hopkinson; Michael Boyd; Martine Cohen-Solal; Colin Farquharson; Andrew A Pitsillides
Journal:  Int J Mol Sci       Date:  2016-12-26       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.